Skip to main content
MTNB logo

Matinas BioPharma Holdings, Inc.

MTNBNYSEAMERICANHealthcareBiotechnology

$2.42Today:- (-)1Y +41.52%

As of Oct 15, 2026 close

Market cap
$1.03M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.48$13.60
Volume (live)
-
Avg. volume (3M)
100.55K

Matinas BioPharma Holdings (MTNB) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Matinas BioPharma Holdings reported total assets of $7.21M and total liabilities of $2.38M. Shareholders' equity was $4.83M, down 36.4% from $7.59M a year earlier. Total debt stood at $1.35M against $4.00M in cash and short-term investments, a net cash position of $2.65M. That puts debt-to-equity at 0.28, compared with 0.38 a year earlier.

Matinas BioPharma Holdings Balance Sheet Analysis

Values in billions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Matinas BioPharma Holdings, Inc. (MTNB) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Mar 2019Dec 2017
Current Assets
Cash and Cash Equivalents0.000.010.000.010.020.010.020.010.01
Short-Term Investments0.000.000.010.020.030.050.010.000.00
Cash & Short-Term Investments0.000.010.010.030.050.060.030.010.01
Accounts Receivable0.000.000.000.000.000.000.000.000.00
Inventory0.000.000.000.000.000.000.000.000.00
Other Current Assets0.000.000.000.010.000.000.000.000.00
Total Current Assets0.000.010.020.030.050.060.030.010.01
Non-Current Assets
Property, Plant & Equipment (Net)0.000.000.010.010.010.000.010.000.00
Long-Term Investments0.000.000.000.000.000.000.000.000.00
Goodwill0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Non-Current Assets0.000.000.000.000.000.000.000.000.00
Total Non-Current Assets0.000.000.010.040.010.010.010.010.01
Total Assets0.010.010.030.080.060.070.040.020.01
Current Liabilities
Accounts Payable0.000.000.000.000.000.000.000.000.00
Short-Term Debt0.000.000.000.000.000.000.000.000.00
Accrued Liabilities0.000.000.000.000.000.00---
Deferred Revenue0.000.000.000.000.000.000.000.000.00
Other Current Liabilities0.000.000.000.000.000.000.000.000.00
Total Current Liabilities0.000.000.000.000.000.000.000.000.00
Non-Current Liabilities
Long-Term Debt0.000.000.000.000.000.003.750.000.00
Deferred Tax Liabilities0.000.000.000.030.000.000.000.000.00
Other Non-Current Liabilities0.000.000.000.000.000.00-3.750.000.00
Total Non-Current Liabilities0.000.000.000.040.000.000.000.000.00
Total Liabilities0.000.010.010.040.010.010.010.000.00
Stockholders' Equity
Common Stock0.000.000.000.000.000.000.000.000.00
Retained Earnings-0.21-0.20-0.18-0.15-0.13-0.11-0.08-0.07-0.05
Accumulated Other Comprehensive Income0.000.000.000.000.000.000.000.000.00
Additional Paid-in Capital0.220.210.200.190.180.170.110.070.06
Shares Outstanding0.010.010.000.000.00----
Total Stockholders' Equity0.000.010.020.040.050.060.030.020.01
Total Liabilities & Equity0.010.010.030.080.060.070.040.020.01

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Matinas BioPharma Holdings Balance Sheet

How much debt does Matinas BioPharma Holdings have?

Matinas BioPharma Holdings had total debt of $1.35M as of Dec 31, 2025, against $4.00M in cash and short-term investments. Its debt-to-equity ratio was 0.28. Total debt was $2.89M a year earlier.

What are Matinas BioPharma Holdings's total assets?

Matinas BioPharma Holdings reported total assets of $7.21M as of Dec 31, 2025, down 43.0% from $12.64M a year earlier. Total liabilities were $2.38M.

What is Matinas BioPharma Holdings's shareholders' equity?

Matinas BioPharma Holdings's shareholders' equity was $4.83M as of Dec 31, 2025, or about $0.75 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition